Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites
Intelligent Bio Solutions (INBS) announced that Princebuild, a UK construction firm with seven sites, has adopted INBS' Intelligent Fingerprinting Drug Screening System, transitioning from saliva testing to fingerprint drug screening. The system offers a more streamlined, in-house solution prioritizing efficiency, accuracy, and employee privacy.
Princebuild joins INBS' portfolio of over 400 accounts across 19 countries, including notable construction companies like Mount Anvil, Hayfield Homes, Stonbury, MBP Structures, and PJ Hegarty & Sons U.K. The technology is used across multiple industries, including construction, mining, manufacturing, transport, law enforcement, and forensics.
Following its FDA 510(k) submission in December 2024, INBS plans to enter the US market in the first half of 2025, targeting expansion in the drug screening products market.
Intelligent Bio Solutions (INBS) ha annunciato che Princebuild, una società di costruzioni del Regno Unito con sette sedi, ha adottato il Intelligent Fingerprinting Drug Screening System di INBS, passando da test salivari a test di screening delle droghe tramite impronta digitale. Il sistema offre una soluzione interna più snella, che prioritizza l'efficienza, l'accuratezza e la privacy dei dipendenti.
Princebuild si unisce al portfolio di INBS, che conta oltre 400 account in 19 paesi, inclusi importanti aziende di costruzione come Mount Anvil, Hayfield Homes, Stonbury, MBP Structures e PJ Hegarty & Sons U.K. La tecnologia viene utilizzata in diversi settori, tra cui costruzione, mineraria, produzione, trasporti, forze dell'ordine e forense.
In seguito alla sua presentazione FDA 510(k) nel dicembre 2024, INBS prevede di entrare nel mercato statunitense nella prima metà del 2025, puntando all'espansione nel mercato dei prodotti per screening delle droghe.
Intelligent Bio Solutions (INBS) anunció que Princebuild, una empresa constructora del Reino Unido con siete emplazamientos, ha adoptado el Intelligent Fingerprinting Drug Screening System de INBS, pasando de pruebas de saliva a un screening de drogas mediante huellas dactilares. El sistema ofrece una solución interna más ágil, priorizando la eficiencia, la precisión y la privacidad de los empleados.
Princebuild se une al portafolio de INBS, que cuenta con más de 400 cuentas en 19 países, incluidas empresas constructoras notables como Mount Anvil, Hayfield Homes, Stonbury, MBP Structures y PJ Hegarty & Sons U.K. La tecnología se utiliza en múltiples industrias, incluyendo construcción, minería, manufactura, transporte, aplicación de la ley y forense.
Tras su presentación a la FDA 510(k) en diciembre de 2024, INBS planea entrar en el mercado estadounidense en la primera mitad de 2025, apuntando a la expansión en el mercado de productos de screening de drogas.
Intelligent Bio Solutions (INBS)는 영국의 건설 회사인 Princebuild가 INBS의 Intelligent Fingerprinting Drug Screening System을 채택하여 침 샘플 검사에서 지문 약물 검사로 전환했다고 발표했습니다. 이 시스템은 효율성, 정확성 및 직원 프라이버시를 우선시하는 보다 간소화된 내부 솔루션을 제공합니다.
Princebuild는 Mount Anvil, Hayfield Homes, Stonbury, MBP Structures 및 PJ Hegarty & Sons U.K.와 같은 주목할 만한 건설 회사를 포함하여 19개국에서 400개 이상의 계정을 보유한 INBS의 포트폴리오에 합류합니다. 이 기술은 건설, 광업, 제조, 운송, 법 집행 및 포렌식을 포함한 여러 산업 분야에서 사용됩니다.
INBS는 2024년 12월 FDA 510(k) 제출 후 2025년 상반기에 미국 시장에 진입할 계획이며, 약물 검사 제품 시장에서의 확장을 목표로 하고 있습니다.
Intelligent Bio Solutions (INBS) a annoncé que Princebuild, une entreprise de construction britannique avec sept sites, a adopté le Intelligent Fingerprinting Drug Screening System d'INBS, passant des tests de salive au dépistage des drogues par empreinte digitale. Le système offre une solution interne plus rationalisée, priorisant l'efficacité, la précision et la confidentialité des employés.
Princebuild rejoint le portefeuille d'INBS, qui compte plus de 400 comptes dans 19 pays, y compris des entreprises de construction notables telles que Mount Anvil, Hayfield Homes, Stonbury, MBP Structures et PJ Hegarty & Sons U.K. La technologie est utilisée dans plusieurs secteurs, y compris la construction, l'exploitation minière, la fabrication, les transports, l'application de la loi et la médecine légale.
Suite à sa soumission FDA 510(k) en décembre 2024, INBS prévoit d'entrer sur le marché américain dans la première moitié de 2025, visant une expansion dans le marché des produits de dépistage des drogues.
Intelligent Bio Solutions (INBS) hat angekündigt, dass Princebuild, ein britisches Bauunternehmen mit sieben Standorten, das Intelligent Fingerprinting Drug Screening System von INBS übernommen hat und von Speicheltests auf Fingerabdruck-Drug-Screening umschaltet. Das System bietet eine effizientere, interne Lösung, die Effizienz, Genauigkeit und die Privatsphäre der Mitarbeiter priorisiert.
Princebuild reiht sich in das Portfolio von INBS ein, das über 400 Konten in 19 Ländern verfügt, einschließlich namhafter Bauunternehmen wie Mount Anvil, Hayfield Homes, Stonbury, MBP Structures und PJ Hegarty & Sons U.K. Die Technologie wird in verschiedenen Branchen eingesetzt, darunter Bau, Bergbau, Fertigung, Transport, Strafverfolgung und Forensik.
Nach der FDA 510(k) Einreichung im Dezember 2024 plant INBS, im ersten Halbjahr 2025 in den US-Markt einzutreten und zielt darauf ab, im Markt für Drogenscreening-Produkte zu expandieren.
- Expansion of client base with addition of multi-site construction firm
- Strong market presence with 400 accounts across 19 countries
- Pending FDA 510(k) submission positions company for US market entry in 2025
- Diversified industry application across multiple sectors
- None.
Insights
The partnership with Princebuild represents a strategic expansion of INBS's presence in the UK construction sector, but more importantly signals momentum ahead of their planned US market entry in H1 2025. The existing portfolio of 400+ accounts across 19 countries demonstrates proven market acceptance of their fingerprint sweat-based drug screening technology.
The construction industry represents a significant market opportunity, particularly as companies shift away from traditional testing methods. The recent FDA 510(k) submission in December 2024 positions INBS to tap into the lucrative US drug screening market, estimated at
For a company with a market cap of just
The technological advantages of INBS's fingerprint sweat-based system over traditional saliva testing are significant. The platform offers simultaneous multi-substance detection with rapid results, addressing key pain points in workplace drug screening. The shorter detection window is particularly innovative, as it focuses on recent drug use relevant to workplace safety rather than historical consumption.
The system's non-invasive nature and respect for privacy align with evolving workplace cultures and employee rights considerations. From an implementation perspective, the simplicity and in-house testing capability reduce operational complexity and dependencies on external labs, potentially leading to substantial cost savings for adopting companies.
Think of it like a modern fingerprint door lock versus traditional keys - it's faster, more efficient and provides better data management capabilities while being less intrusive for users.
Princebuild joins INBS’ portfolio of over 400 accounts in 19 countries as the Company plans to enter the US market in the first half of the 2025 calendar year
NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Princebuild, a leading construction firm with seven sites and operations spanning six key divisions, has adopted INBS’ Intelligent Fingerprinting Drug Screening System. Princebuild has made a strategic decision to move from saliva testing to fingerprint drug screening in order to implement a more streamlined, in-house solution that prioritizes efficiency, accuracy, and respect for employee privacy.
Princebuild, an established construction company in Peterborough, Cambridgeshire, UK and its surrounding areas, has integrated INBS' fingerprint sweat-based technology to enhance safety and compliance across its workforce. The system's simplicity, ease of use, and shorter detection window will enable Princebuild to conduct fast, reliable testing while respecting employees' personal lifestyles.
"By adopting Intelligent Bio Solutions fingerprint sweat-based system, we have transformed our approach to workplace testing," said Cheryl Browne, Human Resources Support Manager at Princebuild. "We wanted a method that ensured safety in our workplace without feeling like we were policing our employees' lifestyles. The simplicity and efficiency of this solution aligns with our company values."
Princebuild joins other leading construction companies that utilize INBS’ innovative drug-testing technology, including Mount Anvil, Hayfield Homes, Stonbury, MBP Structures, and PJ Hegarty & Sons U.K. Ltd. These companies employ INBS’ technology to proactively address substance misuse in the workplace by focusing on ensuring employees are fit for duty at the time of testing.
INBS’ Intelligent Fingerprinting Drug Screening System allows organizations to implement an accurate and efficient testing protocol that meets the needs of the modern workforce. With its ability to detect multiple substances simultaneously and provide rapid results, the system eliminates many challenges associated with traditional testing methods, allowing businesses like Princebuild to focus on cultivating safer, more productive workplaces.
The Company has over 400 accounts across 19 countries. Its Drug Testing Solution is currently being utilized across multiple industries, including construction, mining, manufacturing and engineering, transport and logistics, drug treatment, law enforcement, and forensics. With recent FDA 510(k) submission in December of 2024 and entry into the US market planned for the first half of calendar year 2025, INBS is capitalizing on the rapidly growing drug screening products market.
About Princebuild
Princebuild Limited has cared for, maintained, and built properties since 1971. The company specializes in delivering diverse construction services through six key divisions: construction, small works, insurance, maintenance, building services, and commercial interiors. Over the years, Princebuild has expanded its operations to serve the entire East of England and provides national coverage for larger projects.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
When will INBS enter the US market following its FDA 510(k) submission?
How many accounts does INBS currently have globally?
What industries are currently using INBS' drug testing solution?
What advantages does INBS' fingerprint drug screening offer over saliva testing?
Which major UK construction companies use INBS' drug testing technology?
